Patents by Inventor David Andrew Coates

David Andrew Coates has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250019363
    Abstract: The embodiments of present invention provide processes and an intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide hemisuccinate, and formulations and product forms made by these processes. The embodiments of the present invention further provide for the preparation of lasmiditan acetate, 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide acetate salt, and/or pharmaceutical compositions thereof, and/or uses of lasmiditan acetate and formulations thereof in subcutaneous drug delivery.
    Type: Application
    Filed: September 27, 2024
    Publication date: January 16, 2025
    Inventors: Aktham Aburub, David Andrew Coates, Scott Alan Frank, Mark Steven Kerr, Roger Ryan Rothhaar, Radhe Krishan Vaid
  • Publication number: 20250002482
    Abstract: In an embodiment, the present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type II diabetes mellitus.
    Type: Application
    Filed: September 9, 2024
    Publication date: January 2, 2025
    Inventors: David Andrew COATES, Todd FIELDS, Joseph Daniel HO, Fucheng QU
  • Patent number: 12071423
    Abstract: The embodiments of present invention provide processes for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide hemisuccinate, and formulations and product forms, such as tablets, made by these processes. Additionally, embodiments of the present invention provide tablets including 25 mg, 50 mg, 100 mg, or 200 mg free base equivalent of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate.
    Type: Grant
    Filed: April 14, 2023
    Date of Patent: August 27, 2024
    Assignee: Eli Lilly and Company
    Inventors: Aktham Aburub, David Andrew Coates, Scott Alan Frank, Mark Steven Kerr, Roger Ryan Rothhaar, Radhe Krishan Vaid
  • Publication number: 20240207229
    Abstract: Provided herein are cocrystalline forms including BTK-I useful in the treatment and prevention of diseases which can be treated with a BTK inhibitor, including BTK-associated diseases and disorders, characterizations, and methods of making these cocrystalline forms.
    Type: Application
    Filed: May 11, 2022
    Publication date: June 27, 2024
    Inventors: David Andrew COATES, Lori Raquel HILDEN
  • Patent number: 11999722
    Abstract: The present invention provides a compound of Formula I. or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: June 4, 2024
    Assignee: ELI LILLY AND COMPANY
    Inventors: David Andrew Coates, Timothy Barrett Durham, Richard Duane Johnston, Steven Marc Massey, Patrick Gianpietro Spinazze, Douglas Richard Stack, James Lee Toth
  • Publication number: 20240116932
    Abstract: Provided herein are cocrystalline forms of FGFR3 inhibitors and gallic acid or nicotinamide coformers useful in the treatment and prevention of diseases which can be treated with a FGFR3 inhibitor, including FGFR3-associated diseases and disorders, characterizations and methods of making these cocrystalline forms.
    Type: Application
    Filed: September 6, 2023
    Publication date: April 11, 2024
    Inventors: David Andrew COATES, Lori Raquel HILDEN, Gislaine KUMINEK, Jeffrey A. Peterson
  • Publication number: 20240067628
    Abstract: The present invention relates to specific salts of (1S,5R)-(1?,5?,6?)-N-[1,1-dimethyl-2-[(3-methyl-2-pyridyl)oxy]ethyl]-3-azabicyclo[3.1.0]hexane-6-carboxamide, to pharmaceutical compositions comprising said salts, to methods of using said salts to treat physiological disorders, and to intermediates useful in the synthesis of the salts.
    Type: Application
    Filed: August 7, 2023
    Publication date: February 29, 2024
    Inventors: David Andrew COATES, David Michael REMICK
  • Publication number: 20240059666
    Abstract: The embodiments of present invention provide processes and an intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide hemisuccinate, and formulations and product forms made by these processes. The embodiments of the present invention further provide for the preparation of lasmiditan acetate, 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide acetate salt, and/or pharmaceutical compositions thereof, and/or uses of lasmiditan acetate and formulations thereof in subcutaneous drug delivery.
    Type: Application
    Filed: October 18, 2023
    Publication date: February 22, 2024
    Inventors: Aktham Aburub, David Andrew Coates, Scott Alan Frank, Mark Steven Kerr, Roger Ryan Rothhaar, Radhe Krishan Vaid
  • Patent number: 11834435
    Abstract: The present invention relates to specific salts of (1S,5R)-(1?,5?,6?)-N-[1,1-dimethyl-2-[(3-methyl-2-pyridyl)oxy]ethyl]-3-azabicyclo[3.1.0]hexane-6-carboxamide, to pharmaceutical compositions comprising said salts, to methods of using said salts to treat physiological disorders, and to intermediates useful in the synthesis of the salts.
    Type: Grant
    Filed: September 14, 2022
    Date of Patent: December 5, 2023
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, David Michael Remick
  • Patent number: 11827618
    Abstract: The embodiments of present invention provide processes and an intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide hemisuccinate, and formulations and product forms, such as tablets, made by these processes. Additionally, embodiments of the present invention provide tablets including 25 mg, 50 mg, 100 mg, or 200 mg free base equivalent of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate.
    Type: Grant
    Filed: April 14, 2023
    Date of Patent: November 28, 2023
    Inventors: Aktham Aburub, David Andrew Coates, Scott Alan Frank, Mark Steven Kerr, Roger Ryan Rothhaar, Radhe Krishan Vaid
  • Patent number: 11746115
    Abstract: Solid forms including 7-[[(1S)-1-[4-[(1S)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one and a dihydroxybenzoic acid selected from 2,5-dihydroxybenzoic acid, 2,4-dihydroxybenzoic acid, and 2,3-dihydroxybenzoic acid are provided, as well as pharmaceutical compositions including the solid forms, methods for using the solid forms in treating cancer patients, and methods of making the solid forms.
    Type: Grant
    Filed: August 12, 2022
    Date of Patent: September 5, 2023
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Yizheng Cao
  • Publication number: 20230250092
    Abstract: In an embodiment, the present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type II diabetes mellitus.
    Type: Application
    Filed: March 31, 2023
    Publication date: August 10, 2023
    Inventors: David Andrew COATES, Todd FIELDS, Joseph Daniel HO, Fucheng QU
  • Publication number: 20230250075
    Abstract: The embodiments of present invention provide processes and an intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide hemisuccinate, and formulations and product forms made by these processes. The embodiments of the present invention further provide for the preparation of lasmiditan acetate, 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide acetate salt, and/or pharmaceutical compositions thereof, and/or uses of lasmiditan acetate and formulations thereof in subcutaneous drug delivery.
    Type: Application
    Filed: April 14, 2023
    Publication date: August 10, 2023
    Inventors: Aktham Aburub, David Andrew Coates, Scott Alan Frank, Mark Steven Kerr, Roger Ryan Rothhaar, Radhe Krishan Vaid
  • Publication number: 20230250076
    Abstract: The embodiments of present invention provide processes and an intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide hemisuccinate, and formulations and product forms made by these processes. The embodiments of the present invention further provide for the preparation of lasmiditan acetate, 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide acetate salt, and/or pharmaceutical compositions thereof, and/or uses of lasmiditan acetate and formulations thereof in subcutaneous drug delivery.
    Type: Application
    Filed: April 14, 2023
    Publication date: August 10, 2023
    Inventors: Aktham Aburub, David Andrew Coates, Scott Alan Frank, Mark Steven Kerr, Roger Ryan Rothhaar, Radhe Krishan Vaid
  • Patent number: 11655242
    Abstract: In an embodiment, the present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type II diabetes mellitus.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: May 23, 2023
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Todd Fields, Joseph Daniel Ho, Fucheng Qu
  • Publication number: 20230137090
    Abstract: The embodiments of present invention provide processes and an intermediate for the large-scale preparation of 2,4,6-tri-fluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide hemisuccinate, and formulations and product forms made by these processes. The embodiments of the present invention further provide for the preparation of lasmiditan acetate, 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide acetate salt, and/or pharmaceutical compositions thereof, and/or uses of lasmiditan acetate and formulations thereof in subcutaneous drug delivery.
    Type: Application
    Filed: July 6, 2020
    Publication date: May 4, 2023
    Inventors: Aktham Aburub, David Andrew Coates, Scott Alan Frank, Mark Steven Kerr, Roger Ryan Rothhaar, Radhe Krishan Vaid
  • Publication number: 20230099116
    Abstract: The present invention relates to specific salts of (1S,5R)-(1?,5?,6?)-N-[1,1-dimethyl-2-[(3-methyl-2-pyridyl)oxy]ethyl]-3-azabicyclo[3.1.0]hexane-6-carboxamide, to pharmaceutical compositions comprising said salts, to methods of using said salts to treat physiological disorders, and to intermediates useful in the synthesis of the salts.
    Type: Application
    Filed: September 14, 2022
    Publication date: March 30, 2023
    Inventors: David Andrew COATES, David Michael REMICK
  • Publication number: 20230061806
    Abstract: Solid forms including 7-[[(1S)-1-[4-[(1S)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one and a dihydroxybenzoic acid selected from 2,5-dihydroxybenzoic acid, 2,4-dihydroxybenzoic acid, and 2,3-dihydroxybenzoic acid are provided, as well as pharmaceutical compositions including the solid forms, methods for using the solid forms in treating cancer patients, and methods of making the solid forms.
    Type: Application
    Filed: August 12, 2022
    Publication date: March 2, 2023
    Inventors: David Andrew COATES, Yizheng CAO
  • Patent number: 11490180
    Abstract: The present invention provides for a woven mesh element for an electroacoustic driver enclosure, and to an electroacoustic driver enclosure including such an element, wherein the element includes a plurality of mesh layers, and wherein the plurality of layers includes a layer of Dutch weave mesh preferably including a layer of Dutch Twill weave mesh, and in particular wherein the element includes plural layers of cross woven wire mesh and a layer of Dutch weave wire mesh.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: November 1, 2022
    Assignee: EATON INTELLIGENT POWER LIMITED
    Inventors: David Andrew Coates, John Robbert Kendrick
  • Publication number: 20220153750
    Abstract: The present invention provides novel crystalline salt forms of 6,6-dimethyl-2-{2-[(1-methyl-1H-pyrazol-5-yl)amino]pyrimidin-4-yl}-5-[2-(morpholin-4-yl)ethyl]-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one.
    Type: Application
    Filed: March 19, 2020
    Publication date: May 19, 2022
    Inventors: David Andrew COATES, Sajan JOSEPH, Mark Andrew POLIZZI, David Michael REMICK